Beruflich Dokumente
Kultur Dokumente
Abbott also announced the formal creation of a stand-alone Established Products Division (EPD) concentrated on expanding the market for Abbott's established pharmaceutical portfolio outside of the U.S., particularly focused in emerging markets. GSK's efforts in Brazil build on the company's strategy to increase its presence in emerging markets, particularly in the vaccines space. The key reason for this strategy lies in the sizable (and largely untapped) market opportunities for vaccines in emerging economies.
In 2010, 17% of Pfizer sales were in EMs; for Merck it was 18%; for Abbott, almost a quarter. About 50% of growth in the pharma industry is predicted to come from emerging markets by 2013 (from IMS Health).
In truth, many of these are inter-related, and cultural & infrastructure issues can exacerbate patient record-specific challenges.
We may also have less clarity around the structure & workings of physician practices in these countries
A patient-level approach may provide a more consistent, grounded context in which physicians can respond
To determine the likely global demand for a future anti-infective product conditions (e.g., availability of additional new products).
Challenges
Several related to varying medical practice:
Treated patient varies due to use of traditional (non-pharmaceutical) medicine Differing proportions/profiles for nave vs. treated patients Limited clarity as to which specialties are making the appropriate treatment decision
Patient Categorization
Challenges
Cultural, infrastructure-related, and chart-specific challenges:
Limited physician experience due to very low incidence of disease and by higher levels of untreated patients Varying treatment algorithms/product availability/use from country-to-country Brand availability restrictions biases HCP ability to predict future prescribing behavior Unique confidentiality/privacy concerns about patient information and related physician information
Cross-country Comparison
Challenges
Substantial hurdles exist with this tumor type in EMs Very low incidence tumor type (physicians may only have 1 or 2 patients) Access to patient data (and physicians in some cases) requires administrative clearance at the Director-of-Hospital level Poor Internet access potentially limits the level of complexity in the survey
Sequencing of Therapies
BioVid Corporation
Princeton, NJ 609.750.1400 www.biovid.com